top of page

®

Foveal LLP Independent Investment Research Foveal Research

Independent Investment Research

Foveal in the press

Merck's drug failure deals further blow to Alzheimer's theory

David Crow, New York, 15 February 2017

Biotech turns £10k into £40k in five years: still time to buy?

Kyle Caldwell 12 Septemeber 2015

Drugs firms are increasing their dementia spending

Jill Martin 24 July 2015

Fresh fears of biotech bubble as Axovant soars on NYSE debut

David Crow & Nicole Bullock, New York, 11 June 2015

Bristol's Opdivo cuts risk of lung cancer death for some

Deena Beasly 29 May 2015

Biote ch: Making sense of the science

David Crow 13 April 2015

Big Pharma turns to small biotechs for edge in cancer treatment

Andrew Ward 7 April 2015

New cancer drugs 'vastly overestimated', says contrarian analyst

Ben Hirschler 31 March 2015

bottom of page